2-ethyl-7-nitro-N-(4-(trifluoromethoxy)benzyl)imidazo[1,2-a]pyridine-3-carboxamide | 1334717-90-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-ethyl-7-nitro-N-(4-(trifluoromethoxy)benzyl)imidazo[1,2-a]pyridine-3-carboxamide
• 英文别名: 2-ethyl-7-nitro-N-[[4-(trifluoromethoxy)phenyl]methyl]imidazo[1,2-a]pyridine-3-carboxamide
• CAS: 1334717-90-6
• 化学式: C₁₈H₁₅F₃N₄O₄
• 分子量: 408.337
• InChiKey: BUQIHKBZRDNKNL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Anti-Inflammation Compounds
  申请人：No Zaesung

  公开号：US20140155387A1

  公开（公告）日：2014-06-05

  The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR 4 , C═O, C═S, OP(O)(O), P═O, CH 2 , or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C═O, O, S, CH 2 , or NR 5 ; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.

  本发明涉及一种具有通式（I）的化合物，其中n为0、1、2或；m为0、1、2或3；o为0、1、2或3；W、X、Y和Z分别独立地选自CH、N或N-氧化物；A为NR4、C═O、C═S、OP(O)(O)、P═O、CH2，或从（a）、（b）、（c）、（d）、（e）、（f）、（g）组成的群体中选择的杂环基；V为C═O、O、S、 或NR5；以及其在治疗哮喘、COPD、感染后炎症、关节炎、动脉粥样硬化、疼痛和皮炎等炎症性疾病中的用途。
• COMPOUND INHIBITING ACTIVATION OF THE ENZYME ERK1/2 FOR USE IN THE TREATMENT OF NEUROGENERATIVE ILLNESSES
  申请人：Farmalider, S.A.

  公开号：EP2578212A1

  公开（公告）日：2013-04-10

  The present invention relates to a compound of formula (I) for use as a medicine, in particular for use in the treatment of diseases mediated by the actvation of the protein kinase Erk1/2, such as neurogenerative illnesses like Alzheimer's and related dementia, epilepsy, Parkinson's disease, Huntington's disease, or stroke, and likewise relates to the pharmaceutical compositions containing said compound. The compound of formula (I) effectively inhibits the activation of the enzyme Erk1/2 induced by the tissue plasminogen activator (TPA) and also effectively inhibits the apoptosis generated by the β-amyloid peptide.

  本发明涉及一种用作药物的式(I)化合物，特别是用于治疗由蛋白激酶Erk1/2激活介导的疾病，如阿尔茨海默氏症及相关痴呆症、癫痫、帕金森氏症、亨廷顿氏症或中风等神经退行性疾病，同样还涉及含有所述化合物的药物组合物。式（I）化合物能有效抑制由组织纤溶酶原激活剂（TPA）诱导的 Erk1/2 酶的活化，还能有效抑制由β-淀粉样肽产生的细胞凋亡。
• EP2547678B1
  申请人：——

  公开号：EP2547678B1

  公开（公告）日：2016-03-16
• Anti-Infective Compounds
  申请人：No Zaesung

  公开号：US20130065884A1

  公开（公告）日：2013-03-14

  The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
• Compound Inhibiting Activation of the Enzyme ERK 1/2 To Be Used In The Treatment Of Neurodegenerative Illnesses
  申请人：Navarro Medrano Pilar

  公开号：US20130065966A1

  公开（公告）日：2013-03-14

  The present invention relates to a compound of formula (I) for use as a medicine, in particular for use in the treatment of diseases mediated by the actvation of the protein kinase Erk1/2, such as neurogenerative illnesses like Alzheimer's and related dementia, epilepsy, Parkinson's disease, Huntington's disease, or stroke, and likewise relates to the pharmaceutical compositions containing said compound. The compound of formula (I) effectively inhibits the activation of the enzyme Erk1/2 induced by the tissue plasminogen activator (TPA) and also effectively inhibits the apoptosis generated by the β-amyloid peptide.